Clinical Trials Logo

Essential Fatty Acid Deficiency clinical trials

View clinical trials related to Essential Fatty Acid Deficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT06274788 Not yet recruiting - Malnutrition Clinical Trials

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population

NCT ID: NCT04807478 Withdrawn - Malnutrition Clinical Trials

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Start date: April 1, 2022
Phase:
Study type: Observational

This study will demonstrate Short-, mid-, and long-term safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population

NCT ID: NCT03555019 Active, not recruiting - Clinical trials for Essential Fatty Acid Deficiency

Nutrition Therapy in the Immature Infant (ImNuT)

ImNuT
Start date: April 13, 2018
Phase: N/A
Study type: Interventional

The primary objective of this double-blind randomized study is to assess the effects of an early, enhanced supply of the essential fatty acids (FAs) arachidonic acid (ARA) and docosahexaenoic acid (DHA) on brain maturation, clinical outcomes and quality of growth in immature infants (gestational age <29 weeks) as compared to standard nutrient supply.

NCT ID: NCT01323283 Completed - Clinical trials for Overweight and Obesity

Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children

STOPP-8 OM3
Start date: September 2011
Phase: N/A
Study type: Interventional

This study hypothesizes that supplementation of omega-3 fatty acids (OM3) can increase physical activity, inhibit rapid gain in body weight and BMI in both sedentary and normally active 8 year old children. The purpose is secondarily to explore patterns of associations between OM3 supplementation, baseline and follow-up levels in all studied parameters. The study also aims to study if basal levels of OM3 are correlated with physical activity and to study if there is an association between basal levels of OM3 and the effect of OM3 supplementation on physical activity. To study if there is an effect of OM3 supplementation on triglyceride and LDL cholesterol levels and to study if there are more pronounced effects on children with higher levels. To study if OM3 supplementation, compared with placebo reduce weight increase among children at risk to become overweight. To study if there is an association between effects of OM3 on physical activity, weight and risk markers in blood. To study if there are any gender differences.